Quarterly ResultMay 20, 2026, 07:17 AM
Immunovant Q4 Net Loss $147.9M; IMVT-1402 D2T RA 72.7% ACR20
AI Summary
Immunovant, Inc. reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, alongside significant corporate updates. The company announced positive preliminary Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA), showing clinically meaningful response rates. Concurrently, Immunovant discontinued further development of batoclimab across all indications following failed Phase 3 trials for thyroid eye disease, shifting full focus to IMVT-1402. The company's cash balance of $902.1 million is projected to fund operations through the potential launch of IMVT-1402 in Graves' disease.
Key Highlights
- IMVT-1402 D2T RA trial showed 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16.
- Net loss for Q4 2026 was $147.9 million ($0.73 per share), up from $106.4 million ($0.64 per share) in Q4 2025.
- Net loss for fiscal year 2026 was $505.6 million ($2.77 per share), up from $413.8 million ($2.73 per share) in fiscal year 2025.
- Cash and cash equivalents totaled $902.1 million as of March 31, 2026, providing runway to IMVT-1402 launch in GD.
- R&D expenses for Q4 2026 increased to $142.3 million from $93.7 million in Q4 2025, including $39.0 million for batoclimab discontinuation.
- G&A expenses for Q4 2026 decreased to $17.3 million from $20.2 million in Q4 2025.
Price Impact
More from IMVT